 
 
Official Title:  A Comparative Study Evaluating the Diagnostic Accuracy of Wrist 
Arthroscopy Using the NanoScope Compared to Conventional 
Arthroscopic Instrumentation   
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  20-00356  
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • June 22, 2020  
 
 
  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  
 
   
 
 
 
 
A COMPARATIVE STUDY EVALUATING THE DIAGNOSTIC 
ACCURACY OF WRIST ARTHROSCOPY USING THE NANOSCOPE 
COMPARED TO CONVENTI ONAL ARTHROSCOPIC 
INSTRUMENTATION 
 
Principal Investigator:  
 Nader Paksima, DO MPH  
Department of Orthopedic Surgery, Division of Hand  
S530 1st Avenue, Suite 8  
New York, NY 10016  
212-263-2192  
Additional  Investigator s: Ali Azad, MD  
Department of Orthopedic Surgery, Division of Hand  
301 E. 17th St 
New York, NY 10003  
614-266-7772  
NYULMC Study Number:  i20-00356  
Funding Sponsor:  Not applicable  
IND/IDE Number:  Not applicable  
Regulatory Sponsor :  Not applicable  
Study Product:  Arthrex NanoScope  
Study Product Provider:  Not applicable  
ClinicalTrials.gov 
Number                 Not applicable 
 
Initial version:  6/8/2020  
Study number:  i20-00356   Page ii 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019   
Statement of Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable 
US government research regulations , and institutional research policies and procedures . The Internat ional 
Conference on Harmonis ation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to 
as “ICH -GCP” or “E6”) will be applied only to the extent that it is compatible with FDA and DHHS regulations.  
The Principal Investigator will assure that no deviation from, or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection Training.  
  
Study number:  i20-00356   Page iii 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  Table of Contents  
 
STATEMENT OF COMPLIA NCE  ................................................................................................................ III 
LIST OF ABBREVIATION S........................................................................................................................ VII 
PROTOCOL SUMMARY  ........................................................................................................................... 7-2 
SCHEMATIC OF STUDY DESIGN  ............................................................................................................... 3  
1 KEY ROLES  ......................................................................................................................................... 4  
2 INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONAL E ....................... 4  
2.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ................................................................ 4  
2.2 NAME AND DESCRIPTION OF THE INVESTIGATIONAL AGENT  .............................................................. 4  
2.3 RATIONALE  .................................................................................................................................... 5  
2.4 POTENTIAL RISKS & BENEFITS  ........................................................................................................ 5  
2.4.1  Known Potential Risks  ............................................................................................................. 5  
2.4.2  Known Potential Benefits  ........................................................................................................ 5  
3 OBJECTIVES AND PURPO SE ........................................................................................................... 5  
3.1 PRIMARY OBJECTIVE  ...................................................................................................................... 5  
3.2 SECONDARY OBJECTIVES (IF APPLICABLE ) ...................................................................................... 5  
4 STUDY DESIGN AND ENDPOINTS .................................................................................................... 5  
4.1 DESCRIPTION OF STUDY DESIGN  .................................................................................................... 6  
4.2 STUDY ENDPOINTS ......................................................................................................................... 6  
4.2.1  Primary Study Endpoints  ......................................................................................................... 6  
4.2.2  Secondary Study Endpoints  .................................................................................................... 6  
4.2.3  Exploratory Endpoints  ............................................................................................................. 6  
5 STUDY ENROLLMENT AND WITHDRAWAL  .................................................................................... 6  
5.1 INCLUSION CRITERIA  ...................................................................................................................... 8  
5.2 EXCLUSION CRITERIA  ..................................................................................................................... 8  
5.3 VULNERABLE POPULATIONS  ........................................................................................................... 8  
5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  ............................................................................ 7  
5.5 DURATION OF STUDY PARTICIPATION  .............................................................................................. 7  
5.6 TOTAL NUMBER OF PARTICIPANTS AND SITES .................................................................................. 7  
5.7 PARTICIPANT WITHDRAWAL OR TERMINATION  .................................................................................. 7  
5.7.1  Reasons for Withdrawal or Termination  .................................................................................. 7  
5.7.2  Handling of Participant Withdrawals or Termination  ............................................................... 7  
5.8 PREMATURE TERMINATION OR SUSPENSION OF STUDY  .................................................................... 7  
6 STUDY AGENT (STUDY DRUG, DEVICE, BIOLOGI C, VACCINE ETC.) AND/OR PROCEDURAL 
INTERVENTION  ........................................................................................................................................... 8  
6.1 STUDY AGENT (S) AND CONTROL DESCRIPTION  ................................................................................ 8  
6.1.1  Acquisition  ............................................................................................................................... 8  
6.1.2  Formulation, Appearance, Packaging, and Labeling  .............................................................. 8  
6.1.3  Product Storage and Stability  .................................................................................................. 8  
6.1.4  Preparation  .............................................................................................................................. 8  
6.1.5  Dosing and Administration  ...................................................................................................... 8  
6.1.6  Route of Administration  ........................................................................................................... 8  
6.1.7  Starting Dose and Dose Escalation Schedule  ........................................................................ 8  
6.1.8  Dose Adjustments/Modifications/Delays  ................................................................................. 8  
6.1.9  Duration of Therapy  ................................................................................................................. 8  
6.1.10  Tracking of Dose  ................................................................................................................. 8  
6.1.11  Device Specific Considerations  .......................................................................................... 8  
6.2 STUDY BEHAVIORAL OR SOCIAL INTERVENTION (S) ........................................................................... 8  
Study number:  i20-00356   Page iv 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  6.2.1  Administration of Intervention  .................................................................................................. 8  
6.2.2  Procedures for Training Interventionalists and Monitoring Intervention Fidelity  ..................... 8  
6.2.3  Assessment of Subject Compliance with Study Intervention  .................................................. 8  
6.3 STUDY PROCEDURAL INTERVENTION (S) DESCRIPTION  ..................................................................... 8  
6.3.1  Administration of Procedural Intervention  ............................................................................... 8  
6.3.2  Procedures for Training of Clinicians on Procedural Intervention  ........................................... 8  
6.3.3  Assessment of Clinician and/or Participant Compliance with Study Procedural Intervention
 15 
7 STUDY PROCEDURES AND SCHEDULE  ......................................................................................... 9  
7.1 STUDY PROCEDURES /EVALUATIONS  ............................................................................................... 9  
7.1.1  Study Specific Procedures  ...................................................................................................... 9  
7.1.2  Standard of Care Study Procedures  ..................................................................................... 10 
7.2 STUDY SCHEDULE  ........................................................................................................................ 10 
7.2.1  Screening  .............................................................................................................................. 10 
7.2.2  Enrollment/Baseline  .............................................................................................................. 10 
7.2.3  Intermediate Visits  ................................................................................................................. 10 
7.2.4  Final Study Visit  ..................................................................................................................... 10 
7.2.5  Withdrawal/Early Termination Visit ........................................................................................ 10 
7.2.6  Unscheduled Visit  .................................................................................................................. 10 
7.3 CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  .................................................... 10 
7.4 JUSTIFICATION FOR SENSITIVE PROCEDURES  ................................................................................ 10 
7.4.1  Precautionary Medications, Treatments, and Procedures  .................................................... 10 
7.5 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ........................................................ 11 
8 ASSESSMENT OF SAFETY  ............................................................................................................. 11 
8.1 SPECIFICATION OF SAFETY PARAMETERS  ...................................................................................... 11 
8.1.1  Definition of Adverse Events (AE)  ......................................................................................... 11 
8.1.2  Definition of Serious Adverse Events (SAE)  ......................................................................... 11 
8.1.3  Definition of Unanticipated Problems (UP)  ............................................................................ 11 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ....................................................................................... 12 
8.2.1  Severity of Event  ................................................................................................................... 12 
8.2.2  Relationship to Study Agent  .................................................................................................. 12 
8.2.3  Expectedness  ........................................................................................................................ 12 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP .................................... 13 
8.4 REPORTING PROCEDURES – NOTIFYING THE IRB .......................................................................... 13 
8.4.1  Adver se Event Reporting  ...................................................................................................... 13 
8.4.2  Serious Adverse Event Reporting  ......................................................................................... 14 
8.4.3  Unanticipated Problem Reporting  ......................................................................................... 14 
8.4.4  Reporting of Pregnancy  ......................................................................................................... 14 
8.5 REPORTING PROCEDURES – PARTICIPATING INVESTIGATORS  ......................................................... 14 
8.6 STUDY HALTING RULES ................................................................................................................ 14 
8.7 SAFETY OVERSIGHT  ..................................................................................................................... 15 
9 CLINICAL MONITORING  .................................................................................................................. 15 
10 STATISTICAL CONSIDER ATIONS  .................................................................................................. 15 
10.1  STATISTICAL AND ANALYTICAL PLANS (SAP)  ................................................................................. 15 
10.2  STATISTICAL HYPOTHESES  ........................................................................................................... 15 
10.3  DESCRIPTION OF STATISTICAL METHODS  ...................................................................................... 15 
10.3.1  General Approach  ............................................................................................................. 15 
10.3.2  Analysis of the Primary Efficacy Endpoint(s)  .................................................................... 15 
10.3.3  Analysis of the Secondary Endpoint(s)  ............................................................................. 16 
10.3.4  Safety Analyses  ................................................................................................................ 17 
10.3.5  Adherence and Retention Analyses  .................................................................................. 17 
10.3.6  Baseline Descriptive Statistics  .......................................................................................... 17 
10.3.7  Additional Sub- Group Analyses  ........................................................................................ 17 
Study number:  i20-00356   Page v 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  10.3.8  Multiple Comparison/Multiplicity  ........................................................................................ 17 
10.3.9  Tabulation of  Individual Response Data  ........................................................................... 17 
10.3.1 0 Exploratory Analyses  ........................................................................................................ 18 
10.4  SAMPLE SIZE ............................................................................................................................... 18 
10.5  MEASURES TO MINIMIZE BIAS ....................................................................................................... 18 
10.5.1  Enrollment/Randomization/Masking Procedures  .............................................................. 18 
10.5.2  Evaluation of Success of Blinding  ..................................................................................... 18 
10.5.3  Breaking the Study Blind/Participant  Code  ....................................................................... 18 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DA TA/DOCUMENTS  ................................. 19 
12 QUALITY ASSURANCE AN D QUALITY CONTROL  ....................................................................... 19 
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  ............................................................................. 19 
13.1  ETHICAL STANDARD  ..................................................................................................................... 19 
13.2  INSTITUTIONAL REVIEW BOARD  ..................................................................................................... 19 
13.3  INFORMED CONSENT PROCESS  .................................................................................................... 19 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  ............... 19 
13.3.2  Consent Procedures and Documentation  ......................................................................... 19 
13.4  POSTING  OF CLINICAL TRIAL CONSENT FORM................................................................................. 20 
13.5  PARTICIPANT  AND  DATA CONFIDENTIALITY  ...................................................................................... 20 
13.5.1  Research Use of Stored Human Samples, Specimens, or Data  ...................................... 20 
13.6        FUTURE  USE OF STORED  SPECIMENS .........................................................................................20 
14 DATA HANDLING AND RECORD KEEPING  ................................................................................... 21 
14.1  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  .............................................................. 21 
14.2  STUDY RECORDS RETENTION  ....................................................................................................... 21 
14.3  PROTOCOL DEVIATIONS  ............................................................................................................... 21 
14.4  PUBLICATION AND DATA SHARING POLICY  ..................................................................................... 21 
15 STUDY FINANCES  ............................................................................................................................ 22 
15.1  FUNDING SOURCE  ........................................................................................................................ 22 
15.2  COSTS TO THE PARTICIPANT  ......................................................................................................... 22 
15.3  PARTICIPANT REIMBURSEMENTS OR PAYMENTS  ............................................................................ 22 
16 STUDY ADMINISTRATION ............................................................................................................... 22 
16.1  STUDY LEADERSHIP  ..................................................................................................................... 22 
17 CONFLICT OF INTEREST  POLICY  .................................................................................................. 23 
18 REFERENCES  ................................................................................................................................... 23 
19 ATTACHMENTS  ................................................................................................................................ 23 
20 SCHEDULE OF EVENTS  .................................................................................................................. 23 
  
Study number:  i20-00356   Page vi 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019   
List of Abbreviations  
 
AE Adverse Event/Adverse Experience  
CFR Code of Federal Regulations  
CRF Case Report Form  
CSOC  Clinical  Study Oversight Committee  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DSMB  Data and Safety Monitoring Board  
FFR Federal Financial Report  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
MOP  Manual of Procedures  
N Number (typically refers to participants)  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
OHSR  Office of Human Subjects Research  
PI Principal Investigator  
QA Quality Assurance  
QC Quality Control  
SAE Serious Adverse Event/Serious Adverse Experience  
SOP  Standard Operating Procedure  
US United States  
 
 
Study number:  i20-00356   Page 7 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  Protocol Summary 
Title A Comparative Study Evaluating the Diagnostic Accuracy of Wrist Arthroscopy 
Using the NanoScope Compared to Conventional Arthroscopic Instrumentation  
Short Title  Wrist Arthroscopy Study  
Brief Summary  The purpose of this study is to evaluate the diagnostic efficacy of Arthrex 
NanoScope compared to conventional arthroscopic instruments.  Patients with 
wrist pathology who are indicated for an arthroscopic procedure will be 
enrolled pre- operatively after a thorough discussion of the study aims, risks, 
and benefits .  At the time of surgery, under standard conditions, using 
standard wrist arthroscopy portals, a diagnostic arthroscopy will be performed 
with the Arthrex Nanoscope.  The diagnostic arthroscopy wi ll be performed in a 
stepwise manner for consistency with notation of pathology and intended intervention.  The diagnostic arthroscopy will then be performed with the 
standard arthroscopic equipment, again noting pathology and final 
intervention.  Post -operatively, diagnostic accuracy, incidence of change in 
intervention, and surgeon rated ease of use and confidence will be 
determined .  
Phase  Not applicable  
Objectives  Primary Outcome: To compare the diagnostic sensitivity and specificity of the 
NanoScope compared to conventional arthroscopic instruments.  
 Secondary Outcome: To determine if the diagnostic variability between NanoScope and conventional arthroscopic instruments results in a change in intervention. Surgeon- rated ease of use.  Surgeon- rated di agnostic 
confidence.  
 
Secondary Outcome: To determine the diagnostic correlation between pre-
operative MRI and arthroscopy (NanoScope and conventional).   
 
Methodology  Prospective Cohort Study, Diagnostic  
Study number:  i20-00356   Page 8 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  Primary  Primary  
1. Diagnostic accuracy of Nanoscope compared to conventional arthroscope.  
 
Secondary  
1. Incidence of change in intervention.  
2. Surgeon rated ease of use.  
3. Surgeon rated confidence of diagnosis.  
4. Comparative c orrelation between pre- operative MRI and arthroscopy.  
 
Study Duration  1 year  
Participant Duration  1 day  
Duration of IP 
administration  Not applicable  
Population  N = 3 4, men  and women, age > 18 years, being treated at NYU Langone 
Health  
Study Sites  1. NYU Langone Orthopedic Hospital  
2. Tisch Hospital, NYU Langone Health  
3. NYU Langone Orthopedic Center (38th Street)  
4. Joan H. & Preston Robert Tisch Center at Essex Crossing, NYU 
Langone Health   
Number of participants  34 
Description of Study 
Agent/Procedure  The Arthrex NanoScope is a 1.9 mm wrist arthroscopy system.  
Reference Therapy  Conventional wrist arthroscope  
Key Procedures  Diagnostic wrist arthroscopy of wrists with clinical and imaging confirmation of 
internal derangement (ligament/articular/bony injury).  
Statistical Analysis  Descriptive statistics will be used to provide a quantitative summary of the data 
in the study.  Specifically, the analysis performed included measures of central tendency (mean, median, and mode) and measures of variability (range and standard deviation).  Categorical data will be described in percentages and a 
Chi-squared  test will be employed to detect if these categorical variables are 
related between the two treatment groups with a p value of < .05.  Continuous data will be described in means with standard deviations. A two- tailed Student’s 
T-
test will be employed to compare the means between the two treatment 
groups with a p value of < .05.  
 
  
Study number:  i20-00356   Page 9 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  Schematic of Study Design  
 
 
  
N = 34: Obtain informed consent from patients scheduled to undergo wrist arthroscopy 
at NYU Langone Health. Screen for inclusion and exclusion criteria; obtain history, 
document.  
Perform NanoScope Assessment:  
1. Diagnosis . 
2.Intervention (intended).  
3.Ease of use.  
4.Diagnostic confidence.  
Perform diagnostic wrist arthroscopy with standard portals using NanoScope.  
Perform diagnostic wrist arthroscopy with standard portals using conventional 
instruments.  
Perform Conventional Assessment:  
1. Diagnosis . 
2. Intervention.  
3.Ease of use.  
4.Diagnostic confidence.  
Final Assessments:  
 
1.Compare diagnostic accuracy of NanoScope compared to conventional wrist 
arthroscopy instruments (gold standard).  
a. Sensitivity  
b.Specificity  
2.Determine the rate of change in intervention.  
3.Characterize surgeon- rated ease of use and surgeon- rated diagnostic 
confidence.  
4.Determine the diagnostic correlation between pre- operative MRI and 
arthroscopy (NanoScope and conventional).   
 
Study number:  i20-00356   Page 10 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  1 Key Roles  
Nader Paksima, DO MPH  
Department of Orthopedic Surgery, Division of Hand  
S530 1st Avenue, Suite 8  
New York, NY 10016  
212-263-2192  
 
Ali Azad, MD  
Department of Orthopedic Surgery, Division of Hand  
301 E. 17th St 
New York, NY 10003  
614-266-7772  
 
2 Introduction, Background Information and Scientific Rationale  
 
2.1 Background Information and Relevant Literature  
 
Arthroscopically assisted treatments continue to advance with regard to diagnostic efficacy and treatment capabilities.  Arthroscopy affords 
surgical intervention through a minimally invasive approach, which translates into improved vi sualization, better outcomes, and decreased 
complications.1 Initially developed for larger joints such as the shoulder and knee, arthroscopic technology has advanced to include 
instrumentation amenable to accessing small er joints, including the wr ist.2 However, c onventional instrumentation has inherent size limitations 
resulting in difficulty or inability to access smaller spaces (midcarpal joint, carpometacarpal joint, etc.).  Innovations in  instrumentation, including 
the Arthrex NanoScope, have focused on decreasing instrument size.  The use of these smaller instruments have become commonplace for many 
surgeons  for the diagnosis and treatment of wrist injuries.  However, to our knowledge, there are no studies evaluating the diagnostic efficacy of 
these new arthroscopic visualization systems  compared to conventional arthroscopic instruments .   
 
The purpose of this study is to evaluate the diagnostic accuracy of the Arthrex NanoScope compared to  conventional arthroscopic instruments.  
Additionally, we will analyze if there is difference in intended intervention, ease of use, and diagnosti c confidence, and correlation between pre-
operative MRI and arthroscopic findings.  
2.2 Name and Description  of th e Investigational Agent  
 The Arthrex NanoScope is commonly used for joint arthroscopy.  The instrument itself is not an investigational agent.  We are evaluating the 
instruments diagnostic accuracy compared to conventional instruments.   
Study number:  i20-00356   Page 11 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  The FDA-cleared Arthrex NanoScope System is intended to be used as an endoscopic video camera in a variety of endoscopic surgical 
procedures, including but not limited to: orthopedic, laparoscopic, urologic, sinuscopic, and plastic surgical procedures. The device is also 
intended to be used as an accessory for microscopic surgery . 
  
Instrument: Arthrex NanoScope – Nano Operative Arthroscopy System  
– 1.9 mm single- use, needle- size sterile camera.  
– 13” medical gra de 3- in-1 camera control unit.  
– This device is currently in use for wrist arthroscopy.  The intended purpose of this research study is to compare this devices diagnostic 
accuracy to conventional larger arthroscopic equipment.   
– https://www.arthrex.com/hand- wrist/nano- arthroscopy -system -for-hand- and-wrist 
 
2.3 Rationale  
 The use of these smaller arthroscopic instruments have become commonplace for many surgeons  for the diagnosis and treatment of wrist injuries.  
However, t o our knowledge, there are no studies evaluating the diagnostic efficacy of these new arthroscopic visualization systems  compared to 
conventional arthroscopic instruments.  The purpose of this study is to evaluate the diagnostic accuracy of the Arthrex Nanoscope compared to 
conventional arthroscopic instruments.  Additionally, we will analyze if there is difference in intended intervention, ease of use, and diagnosti c 
confidence.  
2.4 Potential  Risks & Benefits  
2.4.1  Known Potential Risks  
 There are no additional potential risks pertaining to this study involving with the use of the Arthrex NanoScope compared to conventional wrist 
arthroscopy instruments.  The NanoScope will be used with the standard extremity stabilization tower and arthroscopic portals as are used with 
conventional instruments.  The diagnostic arthroscopy using the NanoScope will be performed immediately prior to the diagnostic arthroscopy wi th 
the conventional instrumentation. Estimated additional time to perform the diagnostic arthroscopy with the NanoScope is < 5 minutes , which will 
not result in  subjects  exposure to  risks associated with prolonged anesthesia or surgery . There is also no additional wrist of passing a second 
device (NanoScope) into the wrist joint, in addition to the conventional arthroscope.  
2.4.2  Known Potential Benefits 
 
There are no potential benefits to the participants of this study by virtue of participation.   
Study number:  i20-00356   Page 12 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  3 Objectives and Purpose  
3.1 Primary Objective  
To evaluate the diagnostic accuracy of the Arthrex NanoScope compared to conventional arthroscopic instruments.   
3.2 Secondary Objectives (if applicable)  
To determine if the diagnostic accuracy of the Arthrex NanoScope compared to conventional arthroscopic instruments results in a change in 
intended intervention.  
 
To determine the surgeon- rated ease of use and diagnostic confidence of the Arthrex NanoScope . 
 To determine the diagnostic correlation between pre- operative MRI and arthroscopy (NanoScope and conventional).  The MRI is standard of care 
for evaluation of ligamentous wrist pathology.  It will not be mandated as part of the protocol.   
 
4 Study Design and Endpoints  
4.1 Description of Study Design  
 
• Prospective  cohort study, Diagnostic  
• Single cohort  
o Step 1: NanoScope  
o Step 2: Conventional wrist arthroscopy instruments  
o A single cohort  study , comparing the diagnostic accuracy of the Arthrex NanoScope to conventional instruments (gold standard).  
• Single center  
• Instrument: Arthrex NanoScope  
4.2 Study Endpoints  
4.2.1  Primary Study Endpoints 
 The primary endpoint will be diagnostic accuracy (%) compared to the gold standard of conventional wrist arthroscopy instruments.   The primary endpoint was chosen to determine if smaller instrumentation provides adequate visualization for the diagnosis of wrist pathology and 
can therefore be used as the sole means of  evaluation.  
4.2.2  Secondary Study Endpoints  
 
Study number:  i20-00356   Page 13 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  Secondary endpoints will be a incidence of change in intended intervention and surgeon- rated ease of use and diagnostic confidence.   
 
These secondary endpoints were chosen to determine if a difference in diagnostic accuracy results in a change in intervention as well as to 
determine the number of uses required for surgeon familiarity with the instruments.  
4.2.3  Exploratory Endpoints 
 An exploratory end point will be evaluation of diagnostic accuracy relative to surgeon- rated ease of use and diagnostic confidence to determine if 
there is a learning curve.  
5 Study Enrollment  and Withdrawal 
5.1 Inclusion Criteria  
In order to be eligible to participate in this study, an individual must meet all of the following criteria:  
1. Age > 18 years.  
2. Wrist pathology based on clinical examination/imaging studies undergoing wrist arthroscopy for further evaluation/treatment.  
3. Willingness to participate in the study  
 
5.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study:  
1. Age < 18 years .   
5.3 Vulnerable Subjects  
Vulnerable populations will not be included.  
5.4 Strategies for Recruitment and Retention  
Patients will be recruited from investigator clinical practices. The recruitment plan does not propose to use any NYULMC media services or social 
media. Patients with clinically diagnosed wrist pathology undergoing wrist arthroscopy will be identified by the attending physician and recruited for the study in the office visit when surgery is indicated/scheduled or in the pre-operative area on the day of surgery. The nature of the information 
the subjects will be asked to give about themselves will include objective information relevant to their wrist injury. Only the individuals listed in the 
protocol will have access to the patients study.  
 
As this study does not require long- term patient participation, there are no relevant modalities necessary to enhance participant retention.  
 
The target sample size is 34 patients, recruited from the investigators clinical practice.  
 
Study number:  i20-00356   Page 14 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  5.4.1  Use of DataCore/Epic Information for R ecruitment Purposes  
We will not be using DataCore/Epic for recruitment purposes.  
5.5 Duration of Study Particip ation  
The duration of the study participants’  participation will be one day.  
5.6 Total Number of Participants and Sites  
Recruitment will end when approximately 34 participants are enrolled. It is expected that approximately 34 participants will be enrolled in order to 
produce 34 evaluable participants.   Participants will be enrolled at four 4 NYU study sites:  
1. NYU Langone Orthopedic Hospital  
2. Tisch Hospital, NYU Langone Health  
3. NYU Langone Orthopedic Center (38th Street)  
4. Joan H. &  Preston Robert Tisch Center at Essex Crossing, NYU Langone Health  
5.7 Participant Withdrawal or Termination  
5.7.1  Reasons for Withdrawal or Termination  
Participants are free to withdraw from participation in the study at any time upon request. An investigator may terminate participation in the study 
if: 
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that participation in the study would not be in the best interest of the participant . 
• The participant meets  an exclusion criterion (either newly developed or not previously recognized) that precludes study participation. 
5.7.2  Handling of Participant Withdrawals or Termination  
Participants who withdraw from the study will continue routine post -operative follow up wit h the PI for wrist injury. Their continued care will not be 
affected by their enrollment in this study.  
5.8 Premature Termination or Suspension of Study  
Not applicable.  
 Study may resume once concerns about safety, protocol compliance, data quality are addressed and satisfy the sponsor, IRB and/or FDA.  
6 Study Agent  (Study drug, device, biologic, vaccine  etc.) and/or Procedural Intervention  
The procedural intervention will be a diagnostic wrist arthroscopy using the Arthrex NanoScope followed by a diagnos tic wrist arthroscopy using 
conventional wrist arthroscopy equipment.  
6.1.1  Device Specific Considerations  
Instrument: Arthrex NanoScope – Nano Operative Arthroscopy System  
Study number:  i20-00356   Page 15 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  – 1.9 mm single- use, needle- size sterile camera.  
– 13” medical grade 3- in-1 camera control unit. 
– This device is currently in use for wrist arthroscopy.  The intended purpose of this research study is to compare this devices diagnostic 
accuracy to conventional larger arthroscopic equipment.   
– https://www.arthrex.com/hand- wrist/nano- arthroscopy -system -for-hand- and-wrist 
6.2 Study Behavioral or Social Intervention(s)  
6.2.1  Administration of Intervention 
The attending physician will perform the diagnostic arthroscopy.  
6.2.2  Procedures for Training Interventionalists and Monitoring Intervention Fidelity  
The use of conventional arthroscopic instruments and the Arthrex NanoScope are considered standard of care, and clinicians do not require 
additional training for either.  
6.2.3  Asse ssment of Subject Compliance with Study Intervention 
Not applicable.  
6.3 Study Procedural Intervention(s) Description 
Diagnostic arthroscopy is a well -established procedure.  The procedure itself is not considered the study intervention.  Use of the NanoScope 
using standard extremity stabilization tower and standard wrist arthroscopy portals will be employed.  The instrum entation is similar to 
conventional arthroscopic instrumentation with exception of size, therefore additional training is not required for its use.   
– https://www.arthrex.com/hand- wrist/nano- arthroscopy -system -for-hand- and-wrist 
6.3.1  Administration of Procedural Intervention  
The attending physician will perform the diagnostic arthroscopy.  
6.3.2  Procedures for Training of Clinicians on Procedural Intervention  
The intervention w ill be standardized by having a single operator (attending) perform the diagnostic arthroscopy with the Arthrex NanoScope and 
conventional instruments.  The diagnostic arthroscopy will be performed in a stepwise manner evaluating the ligaments and art icular surfaces of 
the wrist.   
6.3.3  Assessment of Clinician and/or Participant  Compliance with Study Procedural Intervention  
Physician complianc e with procedural intervention will be  through review of the medical record/operative report.  
Study number:  i20-00356   Page 16 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  7 Study Procedures  and Schedule  
7.1 Study Procedures/Evaluations  
7.1.1  Study  Specific Procedures 
 
• Patients undergoing wrist arthroscopy for diagnostic evaluation and treatment of a wrist injury will be enrolled pre- operatively following a 
discussion of the study, risks, benefits, and informed consent.  
• All patients will be positioned supine and placed in an upper extremity traction tower with the shoulder abducted, elbow flexed to 90 
degrees, forearm in neutral position.  
• Standard arthroscopic portals will be made for viewing, instrumentation, inflow, and outflow : 3-4 portal, 6- R portal, midcarpal ulnar (MCU) 
portal, +/ - midcarpal radial (MCR) portal, +/ - 6-U portal . 
• A diagnostic arthroscopy will be performed with the Arthrex NanoScope.  
o Structures evaluated:  
 Radial styloid  
 Proximal scaphoid articular cartilage  
 Scaphoid fossa 
 Radioscaphocapitate (RSC) ligament  
 Long radiolunate (LRL) ligament  
 Short radiolunate (SRL) ligament  
 Scapholunate (SL) ligament  
 Proximal lunate articular cartilage  
 Lunate fossa 
 Triangular fibrocartilage complex (TFCC)  
o T he attending performing the diagnostic arthroscopy will make an initial diagnostic assessment  based on the 
presence/location/severity of synovitis, articular cartilage integrity, ligament injury and determine the intended  treatment .  
• A diagnostic arthroscopy will then be performed with the standard arthr oscopic instruments.  
o Structures evaluated:  
 Radial styloid  
 Proximal scaphoid articular cartilage  
 Scaphoid fossa 
 Radioscaphocapitate (RSC) ligament  
 Long radiolunate (LRL) ligament  
 Short radiolunate (SRL) ligament  
 Scapholunate (SL) ligament  
 Proximal lunate articular cartilage  
 Lunate fossa 
 Triangular fibrocartilage complex (TFCC)  
o T he attending performing the diagnostic arthroscopy will make the final diagnostic assessment  based on the 
presence/location/severity of synovitis, articular cartilage integrity, and ligament  injury and determine the final  treatment .  
Study number:  i20-00356   Page 17 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  • Following the procedure the surgeon will perform a short questionnaire.  
o Surgeon rated visualization. (5 point scale)  
o Surgeon- rated ease of use. (5 point scale)  
o Surgeon- rated diagnostic confidence. (5 point scale)  
• The initial diagnostic assessment and final diagnostic assessment will be compared to determine diagnostic accuracy of the Arthrex 
NanoScope.  
• “Intended” treatment and “final” treatment will be compared to determine if diagnostic variability would result in potential  treatment 
variability.   
• Patients with pre- operative MRIs with a corresponding radiology report will be compared to arthroscopic findings to determination 
correlation between MRI and arthroscopy.  
• No follow -up is required for the purposes of this study.  
7.1.2  Standard of Care Study Procedures  
 
Wrist arthroscopy will be performed with  regional anesthesia or general anesthesia, determined by the anesthesia team pre- operatively.  An 
upper arm tourniquet will be used.  Standard wrist arthroscopy tower will be used.  Access to the joint for visualization, instrumentation, inflow, and 
outflow will use standard portals (see above).  
7.2 Study Schedule  
7.2.1  Screening  
 
Screening Visit (Day - 28 to - 1)  
• During pre- operative clinical evaluation, the attending will determine potential study participants who are indicated for wrist arthroscopy and 
meet the inclusion criteria.   
7.2.2  Enrollment/Baseline  
 Enrollment/Baseline Visit (Visit 1, Day 0)  
• Obtain informed consent of potential participant verified by signature on study informed consent form.  
• Verify inclusion/exclusion criteria.  
• Patient then undergoes wrist arthroscopy with the Arthrex NanoScope followed by conventional instruments (See section 7.1.1).   
7.2.3  Intermediate Visits  
There will be no intermediate visits.  
7.2.4  Final Study Visit  
There will be no final study visit.  
Study number:  i20-00356   Page 18 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  7.2.5  Withdrawal /Early Termination Visit  
Following signing of the consent,, prior to the procedure, the patient is able to withdraw  from the study. .  
7.2.6   Unscheduled Visit  
As study participation takes place over a single day, unscheduled visit is not applicable.  
 
7.3 Concomitant Medications, Treatments, and Procedures  
 
All concomitant prescription medications taken during study participation will be recorded on the case report forms (CRFs). For this protocol, a prescription medication is defined as a medication that can be prescribed only by a properly authorized/licensed clinician. Medications to be reported in the CRF are concomitant prescription medications , over -the-counter medications and non- prescription medications.  
7.4 Justification for Sensitive Procedures  
The justification to for performing a diagnostic arthroscopy with the Arthrex NanoScope is to evaluate diagnostic accuracy as  this device was 
intended for visualization of small joints and is currently in use and considered within standard of care.  
7.4.1  Precautionary Medications, Treatments, and Procedures  
Not applicable.  
7.5 Prohibited Medications, Treatments, and Procedures  
 Treatment with additional upper extremity surgical procedures will not be permitted unless discussed with and approved by the principal 
investigator . 
8 Assessment of Safety  
8.1 Specification of Safety Parameters  
8.1.1  Definition of Adverse Events (AE)  
 An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity during the course of the study.  
Intercurrent illnesses or injuries should be regarded as adverse events.  Abnormal results of diagnostic procedures are consi dered to be adverse 
even ts if the abnormality:  
• results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests 
Study number:  i20-00356   Page 19 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  • is considered by the investigator to be of clinical significance 
 
 
8.1.2  Definition  of Serious Adverse Events (SAE)  
 Serious Adverse Event  
Adverse events are classified as serious or non- serious.  A serious adverse event  is any AE that is:  
• fatal 
• life-threatening  
• requires or prolongs hospital stay  
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
 Important medical events are those that may not be immediately life threatening, but are clearly of major clinical significance. They may je opardize 
the subject, and may require intervention to prevent one of the other serious outcomes noted above. For example, drug overdose or abuse, a seizure that did not result in in- patient hospitalization, or intensive treatment of bronchospasm in an emergency department would typically be 
considered serious.  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non -serious adverse events.  
8.1.3  Definition of Unanticipated Problems (UP)  
 
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all  of  the following criteria:  
• Unexpected in nature, severity, or frequency   (i.e. not described in study -related documents such as the IRB -approved protocol or consent 
form, the investigators brochure, etc)  
• Related or possibly related to participation in the research ( i.e. possibly related means there is a reasonable possibility that the incident 
experience, or outcome may have been caused by the procedures involved in the research) 
• Suggests that the research places subjects or others at greater risk of harm  ( including physical, psychological, economic, or social harm).  
8.2 Classification of an Adverse Event  
8.2.1  Severity of Event  
For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily activities.  
Study number:  i20-00356   Page 20 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  • Moderate  – Events result in a low level of inconvenience or concern with the therapeutic measures. Moderate events may cause some 
interference with functioning.  
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic drug therapy or  other treatment. Severe events are 
usually potentially life- threatening or incapacitating.  
8.2.2  Relationship to Study Agent  
 
For all collected AEs, the clinician who examines and evaluates the participant will determine the AE’s causality based on temporal rel ationship 
and his/her clinical judgment. The degree of certainty about causality will be graded using the categories below.  
• Definitely Related  – There is clear evidence to suggest a causal relationship, and other possible contributing factors can be ruled out. The 
clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to drug administration and cannot be 
explained by concurrent disease or other drugs or chemicals. The response to withdrawal of the drug (dechallenge) should be clinically 
plausible. The event must be pharmacologically or phenomenologically definitive, with use of a satisfactory rechallenge proce dure if 
necessary.  
• Probably Related  – There is evidence to suggest a causal relationship, and the influence of other factors is unlikely. The clinical event, 
including an abnormal laboratory test result, occurs within a reasonable time after administration of the drug, is unlikely to be attributed to 
concurrent  disease or other drugs or chemicals, and follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge 
information is not required to fulfill this definition.  
• Possibly Related  – There is some evidence to suggest a causal relationship (e.g., the event occurred within a reasonable time after 
administration of the trial medication). However, other factors may have contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it can be flagged as requiring more information and later be upgraded to “probably related” or  “definitely related,” as appropriate.  
• Unlikely to be related  – A clinical event, including an abnormal laboratory test result, whose temporal relationship to drug adm inistration 
makes a causal relationship improbable (e.g., the event did not occur within a reasonable time after administration of the trial medication) 
and in which other drugs or chemicals or underlying disease provides plausible explanations (e.g., the participant’s clinical condition,  other 
concomitant treatments).  
• Not Related  – The AE is completely independent of study drug administration, and/or evidence  exists that the event is definitely related to 
another etiology. There must be an alternative,  definitive etiology documented by the clinician.  
8.2.3  Expectedness 
 
Dr. Nader Paksima will be responsible for determining whether an AE is expected or unexpected. An AE will be considered unexpected if the 
nature, severity, or frequency of the event is not consistent with the risk information previously described for the study agent.  
 
8.3 Time Period and Frequency for Event Assessment and Follow -Up 
 The occurrence of an AE or SAE may come to the attention of study personnel during study visits and interviews of a study participant presenting 
for medical care, or upon review by a study monitor. All AEs including local and systemic reactions not meeting the criteria for SAEs will be 
captured on the appropriate RF. Information to be collected includes event description,  time of onset, clinician’s assessment of severity, 
Study number:  i20-00356   Page 21 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  relationship to study product (assessed only by those with the training and authority to make a diagnosis), and time of resolution/stabilization of the 
event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate 
resolution.  
 
Any medical condition that is present at the time that the participant is screened will be considered as baseline and not rep orted as an AE. 
However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data collection system throughout the study.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. 
AEs characterized as intermittent require documentation of onset and duration of each episode.  
 The PI will record all reportable events with start dates occurring any time after informed consent is obtained until 7 (for non- serious AEs) or 30 
days (for SAEs) after the last day of study participation. At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information until resolution or stabilization.   
 All unresolved adverse events should be followed by the investigator until the events are resolved, the subject is lost to follow -up, or the adverse 
event is otherwise explained.  At the last scheduled visit, the investigator should instruct each subject to report any subsequent event(s) that the subject, or the subject’s personal physician, believes might reasonably be related to participation in this study.  The investigator should notify the study sponsor of any death or adverse event occurring at any time after a subject has discontinued or terminated study participation that m ay 
reasonably be related to this study.  The sponsor should also be notified if the investigator should become aware of the deve lopment of cancer or 
of a congenital anomaly in a subsequently conceived offspring of a subject that has participated in this study.   
8.4 Reporting Procedures  – Notifying the IRB  
8.4.1  Adverse Event Reporting 
Each adverse event will be reviewed on a case- by-case basis by the study physician and Principle Investigator to determine any risks to the 
participants’ continued participation in the study.   There are no predefined stopping rules for the study. The following table will be used to document such adverse events:  
 
Subject Name  Procedure Date  Signs of Adverse 
Event  Signature of Monitor  Date and Time  
     
  
Adverse events will be reported to the IRB within 5 days of the event. Acute medical care will be provided as appropriately n eeded. The report will 
be submitted to the IRB on an adverse event CRF and an IRB reportable events form. If the subject reports their inability to continue the study, 
significant discomfort, or other negative effects, the procedure will terminate immediately, and any generated data will be destroyed. We do not anticipate any such adverse events as all pre- operative or post -operative assessments and interventions are standard of care.  
 
Study number:  i20-00356   Page 22 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  The data of adverse events under this monitoring plan will be assessed by the PI quarterly, every 3 months. Results and all adverse outcomes will 
be communication to the IRB by the Investigator when required. Every 12 months a review of all subject records, the progress of the study, any 
safety issues and adverse events that have occurred will be conducted and a report will be included during the annual IRB continuation review.  
 
8.4.2  Serious Adverse Event Reporting  
If an event occurs and is determined to be a SAE, it will be documented and monitored as described for AE’s, with the addition that the Investigator will notify the IRB directly within 1 business day. Appropriate acute medical care will be provided  to the subject.  
8.4.3  Unanticipated Problem Reporting  
 Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an UP report form. It is the s ite investigator’s 
responsibility to report UPs to their IRB The UP report will include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP.  
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
 
• UPs that are SAEs will be reported to the IRB within 1 week of the investigator becoming aware of the event.  
• Any other UP will be reported to the IRB within 1 week of the investigator becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by an institution’s written reporting procedures), the supporting 
agency head (or designee), and OHRP within  1 week of the IR’s receipt of the report of the problem from the inv estigator.  
 
8.4.4  Reporting of P regnancy 
Patients who are pregnant will not be included in this study.  
8.5 Reporting Procedures – Participating Investigators  
This is not a multi -center clinical trial.  
8.6 Study Halting Rules  
 Not applicable.  
8.7 Safety Oversight  
 
Study number:  i20-00356   Page 23 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  It is the responsibility of the Principal Investigator to oversee the safety of the study at his/her site.  This safety monitoring will include careful 
assessment and appropriate reporting of adverse events as noted above, as well as the construction and implementation of a site data and safety -
monitoring plan. Medical monitoring will include a regular assessment of the number and type of serious adverse events.  
9 Clinical Monitoring 
 Clinical site monitoring is conducted to ensure that the rights and well -being of  human subjects are protected, that the reported trial data are 
accurate, complete, and verifiable, and that the conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable regulatory requirement(s ). 
 
• The PI will conduct on- site monitoring for initial assessment with a comprehensive review of the data.  
• Independent audits will be conducted by the sub- investigators  to ensure monitoring practices are performed consistently across all 
participating sit es. 
• Each clinical site will perform internal quality management of study conduct, data collection, documentation and completion. An 
individualized quality management plan will be developed to describe a site’s quality management.  
 
10 Statistical Considerations 
10.1 Statistical and Analytical Plans (SAP)  
A formal SAP will  be completed prior to database lock.  
10.2 Statistical Hypotheses 
 
We hypothesize that there will be no difference in the diagnostic accuracy of the Arthrex NanoScope compared to conventional arthroscopi c 
instruments.  
10.3 Description of Statistical Methods  
10.3.1  General Approach  
Descriptive statistics will be used to provide a quantitative summary of the data in the study.  Specifically, the analysis performed included measures of central tendency (mean, median, and mode) and measures of variability (range and standard deviation). Categorical data will be described in percentages and a Chi- squared  test will be employed to detect if these categorical variables are related between the two treatment 
groups with a p value of < .05.  Continuous data will be described in means with standard deviations. A two -tailed Student’s T -test will be 
employed to compare the means between the two treatment groups with a p value of < .05.  
 
Study number:  i20-00356   Page 24 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  10.3.2  Analysis of the Primary Efficacy Endpoint(s) 
Primary  
1. Diagnostic accuracy of Nanoscope compared to conventional arthroscope.  
 
Diagnostic accuracy of the Arthrex Nanoscope will be described as a incidence/percentage compared to the diagnosis determined by wrist 
arthroscopy with conventional instruments.  
10.3.3  Analysis of the Secondary Endpoint(s)  
Secondary  
1. Incidence of change in int ervention.  
2. Surgeon rated ease of use.  
3. Surgeon rated confidence of diagnosis.  
4. Correlation between pre- operative MRI findings and arthroscopic findings.  
 Secondary endpoints will be described using incidence/percentage.  A t wo-tailed Student’s T -tests will be employed to compare the means  of 
surgeon- rated outcomes between the Arthrex NanoScrope and conventional instruments groups with a p value of .05.   
10.3.4  Safety Analyses  
Safety endpoints will be analyzed as summary statistics during treatment. Adverse events will be PI reported. Adverse events leading to premature discontinuation from the study will be presented in a table.  
10.3.5  Adherence and Retention Analyses  
Not applicable.  
10.3.6  Baseline Descriptive Statistics  
Not applicable.  Each patient will serve as an internal control.  
10.3.7  Tabulation of Individual Response Data  
Individual participant data will be listed by measure and time point.  
10.3.8  Exploratory Analyses  
Not applicable.  
10.4 Sample Size  
34 participants will be recruit ed to meet a goal of evaluable participants for the study.  
 
• Outcome measure: diagnostic accuracy  
• Test statistic : descriptive statistics  
Study number:  i20-00356   Page 25 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  • Null hypoth esis: We hypothesize that there will be no difference in the diagnostic accuracy of the Arthrex NanoScope compared to 
conventional arthroscopic instruments.  
• Type I error rate (alpha) : 0.95 
• Power level: 0.819 
• Dropout: Not applicable.  
• Approach to handling withdrawals and protocol violations: Not applicable.  
Statistical method used to calculate the sample size : At 90% prevalence, in order to detect a change in sensit ivity (true -positive) between .70 
(sensitivity of MRI) and .90 (sensitivity of arthroscopy), we would need a minimum of 34 subjects with a minimum of 31 who had a ligamentous wrist 
injury  (see table below).   This was determine with the guidance of the Center for Clinical Research.    
 
 
Study number:  i20-00356   Page 26 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019   

Study number:  i20-00356   Page 27 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  10.5 Measures to Minimize Bias  
10.5.1  Enrollment/Randomization/Masking Procedures 
Enrollment will not be randomized. Each patient will serve as an internal control.  
10.5.2  Evaluation of Success of Blinding  
Blinding is not possible and not indicated for this study design.  
10.5.3  Breaking the Study Blind/Participant Code  
Not applicable.  
11 Source Documents and Access to Source Data/Documents  
Access to study records will be limited to IRB- approved members of the study team. The investigator will permit study -related monitoring, audits, 
and inspections by the IRB/EC , the sponsor, government regulatory bodies, and University compliance and quality assurance groups of all study 
related documents (e.g. source documents, regulatory documents, data collection instruments, study data etc.).  The investigator will ensure the 
capability for inspections of applicable study -related facilities (e.g. pharmacy, diagnostic laboratory, etc.).  
 Participa tion as an investigator in this study implies acceptance of potential inspection by government regulatory authorities and app licable 
University compliance and quality assurance offices.  
12 Quality Assurance and Quality Control  
 
QC procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. 
Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
 Following written SOPs, the monitors will verify that the clinical trial is conducted and data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Ma nufacturing 
Practices (GM P)). 
 The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities.  
13 Ethics/Protection of Hum an Subjects  
13.1 Ethical Standard  
 The investigator will ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.  
Study number:  i20-00356   Page 28 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  13.2 Institutional Review Board  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB for  review and approval. 
Approval of both the protocol and the consent form must be obtained before any participant is enrolled. Any amendment to the protocol will require 
review and approval by the IRB before the changes are implemented to the study. All changes to the consent form will be IRB approved; a 
determination will be made regarding whether previously  consented participants need to be re- consented.  
13.3 Informed Consent Process  
13.3.1  Consent and Other Informational Documents Provided to Participants 
Consent forms describing in detail the study agent, study procedures, and risks are given to the participant and wr itten documentation of informed 
consent is required prior to starting intervention/administeri ng study product. The consent materials are submitted with this protocol . 
13.3.2  Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s 
study participation. Informed consent will occur in the office visit when surgery is indicated/scheduled or in the pre- operative area on the day of 
surgery . If informed consent is obtained the day of surgery, it will occur in the pre- operative area where informed consent for the procedure occurs, 
providing a privacy.  Patients will be given sufficient time to determine their involvement.  Informed consent for surgery is obtained 30 minutes to 1 
hour prior to the procedure.  Discussion of the study will occur at the same time.  If the patient does not feel that they have had enough time to contemplate involvement, they will not be included in the study.  Only patients who are comfortable with involvement and express that they have had sufficient time to consider involvement will be asked to sign the consent. Extensive discussion of risks and possible benefits of participation 
will be provided to the participants and their families. Consent forms will be IRB -approved and the participant will be asked to read and review the 
document. The investigator will explain the research study to the participant and answer any questions that may arise. All participants will receive 
a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of their rights as 
research participants. Participants will have the opportunity to carefully review the written consent form and ask questions prior to signing. The participants should have the opportunity to discuss the study with their doctor or relatives  or think about it prior to agreeing to participate. The 
participant will sign the informed consent document prior to any procedures being done specifically for the study. The participants may w ithdraw 
consent at any time throughout the course of the trial. A copy of the  signed informed consent document will be given to the  participants for their 
records. The rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.  
 A copy of the signed informed consent document will be stored in the subject’s research record. The consent process, including the name of the 
individual obtaining consent, will be thoroughly documented in the subject’s research record.  Any alteration to the standard consent process (e.g. 
use of a translator, consent document presented orally, etc.) and the justification for such alteration will likewise be documented.  
13.4 Posting of Clinical Trial Consent Form  
Not applicable.  
Study number:  i20-00356   Page 29 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  13.5 Participant and Data Confidentiality  
Information about  study subjects will be kept confidential and managed according to the requirements of the Health Insurance Portability and 
Accountability Act of 1996 (HIPAA).  Those regulations require a signed subject authorization informing the subject of the following :  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of t heir PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains the ability  to use all information 
collected prior to the revocation of subject authorization.  For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled stu dy period.  
 
Paper consent forms will be kept in a designated file box in the principal investigators locked office.  
 
All study data will be collected, organized and stored on a safe, MCIT managed network drive. A “key” file will be created associating the MRN to a numerical value (1, 2, 3…). Once the data collection portion of the study is complete, all data sheets will be de- identified by permanently removing 
the “key” file containing identifiable information from the database (MRN).  
 
The study database will only be accessed by the principal investigator and sub- investigators.  
 Study data will be stored for no fewer than 3 years after completion of data collection to ensure appropriate time for data analysis, as well as need 
for re -review in analysis, write -up, publication and peer -review processes.  
13.6 Future Use of Stored Specimens  
Not applicable.  
14 Data Handling and Record Keeping  
14.1 Data Collection and Management Responsibilities  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. The investigator is responsible for 
ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  
 All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black ink is required to ensure 
clarity of reproduced copies. When making changes or corrections, cross out the original entry with a single line, and initial and date the change. 
DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORI GINAL.  
 Copies of the electronic CRF (eCRF) will be provided for use as source documents and maintained for recording data for each participant enrolled in the study. Data reported in the eCRF derived from source documents should be consistent with the source documents or the discrepancies should be explained and captured in a progress note and maintained in the participant’s official electronic study record.  
 
Study number:  i20-00356   Page 30 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical laboratory data will be entered into a 21 
CFR Part 11- compliant data capture syst em. The data system includes password protection and internal quality checks, such as automatic range 
checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.  
14.2 Study Records Retention  
Study documents  will be retained for the longer of 3 years after close- out, 5 years after final reporting/publication, or  2 years after the last approval 
of a marketing application is approved for the drug for the indication for which it is being investigated or 2 years after the investigation is 
discontinued and FDA is notified if no application is to be filed or if the application has not been approved for such indication. No records will be 
destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer need to be retained.  
14.3 Protocol Deviations  
 A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of Pr ocedures  (MOP)  requirements. The noncompliance 
may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by the site and implemented promptly.  
 These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncom pliance, sections 5.20.1, and 5.20.2.  
 It is the responsibility of the site PI/study staff to use continuous vigilance to identify and report deviations within 7 working days of identification of 
the protocol deviation, or within 7 working days of the scheduled protocol- required activity.  
  Protocol deviations must be reported to the local IRB per their guidelines. The site PI/study staff is responsible for knowing and adhering to their 
IRB requirements. Further details about the handling of protocol deviations will be included in the MOP.  
 
14.4 Publication and Data Sharing Policy  
 This study will comply with the NIH Public Access Policy, which ensures that the public has access to the published results of NIH funded research. It requires  scientists to submit final peer -reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central 
upon acceptance for publication.  
 
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials registration policy as a condition 
for publication. The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause- and-effect relationship between a medical intervention and a health outcome. Medical 
interventions include drugs, surgical procedures, devices, behavioral treatments, process -of-care changes, and the like. Health outcomes include 
Study number:  i20-00356   Page 31 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  any biomedical or health- related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. The 
ICMJE policy, and the Section 801 of the Food and Drug Administration Amendments Act of 2007, requires that all clinical trials be registered in a 
public trials registry such as ClinicalTrials.gov, which is sponsored by the National Library of Medicine. Other biomedical journals  are considering 
adopting similar policies. For interventional clinical trials performed under NIH IC grants and cooperative agreements, it is the grantee’s 
responsibility to register the trial in an acceptable registry, so the research results may be considered for publication in ICMJE member journals. The ICMJE does not review specific studies to determine whether registration is necessary; instead, the committee recommends that researchers who have questions about the need to register err on the side of registration or consult the editorial office of the journal in which they wish to 
publish.  
 FDAAA mandates that a "responsible party" (i.e., the sponsor or designated principal investigator) register and report results of certain "applicable clinical trials":  
 
• Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase I investigations of a product subject to FDA regulation;  
• Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation (other than small feasibility studies) and 
pediatric postmarket surveillance studies.  
• NIH grantees must take specific steps to ensure compliance with NIH implementation of FDAAA.  
15 Study Finances  
15.1 Funding Source  
There is no funding source.  
15.2 Costs to the Participant  
There will be no additional cost to the participant as a result of participating in the study.  
15.3 Participant  Reimbursements or Payments  
Participants will not be compensated or provided with any incentives for study participation.  
16 Study Administration 
16.1 Study Leadership  
The study leadership will consist of the principal investigator.  
17 Conflict of Interest  Policy  
The independence of this study from any actual or perceived influence, such as by the pharmaceutical industry, is critical. Therefore any actual 
conflict of interest of persons who have a role in the design,  conduct, analysis, publication, or any aspect of this trial will be disclosed and 
managed. Furthermore, persons who have a perceived conflict of interest will be required to have such conflicts managed in a way that is 
Study number:  i20-00356   Page 32 
Version: June 8, 2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the study sponsor  
Interventional Template Version: 11 January 2019  appropriate to their participation in the trial. The study leadership has established policies and procedures for all study group members to disclose 
all conflicts of interest and will establish a mechanism for the management of all reported dualities of interest.   
 Any investigator who has a conflict of interest with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by the NYU Langone Conflict of Interest Management Unit (CIMU)  with a Committee-
sanctioned conflict management plan that has been reviewed and approved by the study sponsor prior to participation in this study. All NYULMC  
investigators will follow the applicable  conflict of interest policies . 
 
18 References  
 
1.  Bednar JM, Osterman AL. The role of arthroscopy in the treatment of traumatic triangular fibrocartilage injuries. Hand Clin. 1994;10(4):605- 614. 
2.  Michelotti BF, Chung KC. Diagnostic Wrist Arthroscopy. Hand Clin. 2017;33(4):571- 583. doi:10.1016/j.hcl.2017.06.004  
 
19 Attachments  
These documents are relevant to the protocol, but they are not considered part of the protocol.  They are stored and modified separately. As such, 
modifications to these documents do not require protocol amendments.  
 
 